Otrivin spray Nazal complex. scrapper. 0.6mg / mL + 0.5mg / mL 10ml vial with CMV doz.ustr

Description

Composition
Active substance:
Per 1 ml: pratropiya bromide monohydrate 0.6 mg
Xylometazoline hydrochloride 0.5 mg.
Excipients:
glycerol (85%) – 27.9 mg disodium edetate dihydrate – 0.5 mg, concentrated hydrochloric acid – to pH 4.5, sodium hydroxide – to pH 4.5, water – up to 1 ml.
Description:
Nasal spray as a clear, colorless or slightly colored solution, practically odorless.
Product form:
10 ml vial formulation of PVP equipped with a dosing pump action device with the tip of polypropylene and polyethylene protective cap. The vial together with instructions for use placed in a cardboard box.
Contraindications
Increased sensitivity to the drug, hypersensitivity to atropine or similar compounds (hyoscyamine, scopolamine), glaucoma, post transsphenoidal hypophysectomy, surgery on the brain membranes (history), pregnancy and lactation, atrophic rhinitis, age up to 18 years.
Dosage
0.6 mg + 0.5 mg / ml
Indications
– symptomatic treatment of edema and hyperemia of the nasal cavity; – acute respiratory illness with symptoms of rhinitis (common cold), accompanied by congestion; – acute allergic rhinitis; – hay fever; – sinusitis.
Interaction with other drugs
The drug is incompatible with MAO inhibitors, tri- and tetracyclic antidepressants, as may increase the sympathomimetic effect of xylometazoline. Sympathomimetic drugs cause the release of catecholamines, including noradrenaline having vasoconstrictive effect, thereby increasing blood pressure. With a significant increase in blood pressure treatment with the drug should be discontinued Otrivin® complex, a symptomatic treatment. When concomitant administration of other drugs with anticholinergic activity, may increase the anticholinergic effects of ipratropium bromide.
Overdose
With nasal administration of the drug complex Otrivin® acute overdose is unlikely because absorption of the drug is extremely small. Symptoms in case of overdose ksilometazolina clinical picture is characterized by nausea, sweating, low body temperature, headache, bradycardia, disturbance of accommodation, hypertension, respiratory depression, coma. Hypertension may be replaced by hypotension. Excessive use of ipratropium bromide overdose is unlikely due to the negligible absorption of substances in the blood, but can develop dry mouth, difficulty of accommodation, tachycardia. Treatment: symptomatic therapy is carried out under the supervision of a physician. A considerable overdose can cause symptoms associated with anticholinergic action ipratropium bromide of the CNS, including hallucinations, to eliminate assigning cholinesterase inhibitors.
pharmachologic effect
Pharmacological group:
R01AB06
Pharmacodynamics:
Xylometazoline refers to a group of local vasoconstrictive agents (decongestants) c-alpha adrenomimeticheskim action causes vasoconstriction of nasal mucosa, thus eliminating mucosal swelling and nasal congestion. Relieves nasal, easier nasal breathing in rhinitis. Ipratropium bromide possesses anticholinergic effect. When intranasal application reduces nasal secretion during the stopping of the nose due to competitive inhibition of cholinergic receptors located in the epithelium of the nasal cavity. At therapeutic concentrations does not irritate the mucous membrane, it does not cause flushing. The drug takes effect after 5-10 minutes and has a stable effect over 6-8 hours.
Pharmacokinetics:
Intranasal application of Ipratropium bromide and Xylometazoline hydrochloride is little absorbed and are present in blood plasma in minor amounts.
Pregnancy and breast-feeding
Use of the drug during pregnancy and breast-feeding period is contraindicated.
Conditions of supply of pharmacies
Without recipe
side effects
Determination of the frequency of adverse reactions: very often (> 10); common (> 1/100,
special instructions
Before use, clean the nasal passages. It should not be used for a long time, for example, in chronic rhinitis. Avoid release of the drug into the eyes or around the eyes. In case of contact there may be a temporary blurred vision, irritation, pain, redness of the eye, may develop acute angle-closure glaucoma. It should be abundantly flush eyes with cold water in case of contact with their drug and consult a doctor if the pain in the eyes or blurred vision. The effect on the ability to drive vehicles and mechanisms Application Otrivin® complex drug at therapeutic doses, did not affect the ability to drive vehicles and mechanisms.
Storage conditions
The drug should be stored in reach of children at a temperature not higher than 25 ° C.
Dosing and Administration
Intranasally. For patients aged over 18 years: 1 injection into each nostril 3 times / day. The drug is used no more than 7 days without consulting a doctor. Prolonged use of Xylometazoline can cause swelling of the nasal mucosa and increase secretions, which is caused by the development of increased cell sensitivity to the active ingredients of the drug, so called backfire. 1 Injection preparation Otrivin® complex contains about 70 mg Xylometazoline hydrochloride and 84 mg of ipratropium bromide.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist